Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, England–(BUSINESS WIRE)–Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical…
LUGANO, Switzerland & BELLINZONA, Switzerland & GARDANNE, France–(BUSINESS WIRE)–Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to…
The FDA has granted first approvals for the generic versions of Lyrica to Alembic Pharmaceuticals, Alkem Laboratories, Amneal Pharmaceuticals, Dr. Reddy’s Laboratories, InvaGen Pharmaceuticals, MSN Laboratories Ltd., Rising Pharmaceuticals, Inc., Sciegen Pharmaceuticals Inc., and Teva Pharmaceuticals.
Yellow Wood Partners will buy the Dr. Scholl’s foot care business from Bayer for a purchase price of $585 million, the companies said amid Bayer’s voluntarily recall of a product in the USA.
Bayer is voluntarily recalling two lots of Kogenate FS antihemophilic factor (recombinant) 2000 IU vials in the United States to the patient level, the company said Monday in a statement.
Data supporting the application demonstrated that the investigational subcutaneous formulation improved quality of life, reduced administration time, lowered rates of…
Clinical neuropathic pain expert Prof. Sommer and long-time pain pharma industry expert Dr. Langner to consult Algiax Pharmaceuticals in the…
Leading European life sciences investment firm Medicxi today announces the closing of Medicxi III, a new €400 million fund. This brings the total amount raised by Medicxi in the last three years to over $1 billion.
Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga® (regorafenib) and Bristol-Myers Squibb’s / Ono’s anti-PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab) in patients with micro-satellite stable metastatic colorectal cancer (MSS mCRC), the most common form of mCRC.1
Quotient Sciences and global investment firm Permira today announced that a company backed by the Permira Funds has signed a definitive agreement to acquire a majority stake in Quotient from companies controlled by GHO Capital and other investors for an undisclosed sum.